26
Aug
2020
An Underappreciated Aspect of Power: Listening
As the summer draws to a close, I thought TR readers might enjoy a final August distraction. I’ve always been an avid reader, and lately, I’ve found myself increasingly drawn to the history and science of American politics. On the history front, and inspired by Stanford professor Jeffrey Pfeffer (an expert on power and leadership), I’ve started Robert Caro’s famously... Read More
24
Aug
2020
Insurance Reform, Not Executive Orders, Is the Best Tool to Protect U.S. Patients and U.S. Pharmaceutical Innovation
With today’s Aug. 24 deadline looming, it’s important to explain how President Trump’s “most favored nations” executive order to purportedly lower drug prices would actually backfire, and hurt patients both at home and abroad. The order, which ties prices for certain drugs paid for by Medicare to the lowest prices paid in other countries, including Canada and much of Europe,... Read More
20
Aug
2020
Spiritual Renewal in the North Cascades, and Facing Homelessness
All of us need some time and space for spiritual renewal. Especially in a year like 2020. Mountain climbing does it for me. Last weekend, I was fortunate to get out to Mt. Shuksan in the remote North Cascades of Washington. It was a gorgeous climb, led by my friends and partners at Alpine Ascents International. The climb was a... Read More
18
Aug
2020
Antibiotic Resistance Looms Large in Pandemic; CRISPR Phages Show Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Aug
2020
A Microbiome Turnaround, Novavax Gears Up, & Moderna Commits to 100m Doses
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Aug
2020
From Rio to Rome: Rosana Kapeller on The Long Run
Today’s guest on The Long Run is Rosana Kapeller. She’s the president and CEO of Cambridge, Mass.-based ROME Therapeutics. ROME aims to discover and develop drugs based on emerging science in what is sometimes called the “repeatome.” These are long repeat stretches of DNA that scientists until recently knew very little about, and still have a lot to learn about... Read More
11
Aug
2020
SpringWorks Faces Readout for Gamma Secretase Inhibitor; Eyes BCMA Combo for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2020
GSK’s BCMA Antibody Gets OK, Biogen Teams With Denali & A Telemedicine Megadeal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2020
COVID-19 Is Driving a Shift in How We Value Diagnostic Tests
There are very few things many of us can say with 100 percent certainty. But after three decades of experience in molecular diagnostics and the life science industry, I can say this: never before has the healthcare profession, and even the American public, been so laser-focused on diagnostics. For all the tragedy it has caused, the COVID-19 pandemic has shone... Read More
5
Aug
2020
Generation Bio Blazes New Trail in Gene Therapy with Non-Viral Approach
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2020
Versant Ventures Wagers $35M on Cytokine Engineering with Bright Peak
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2020
Akili Interactive Delivers Prescription Level Treatment via Video Games
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Aug
2020
Ohana Biosciences and Sperm Biology: The Other Half of the Fertility Equation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Jul
2020
Closing Medicine’s Feedback Gap: Can Tech Help Integrate Clinical Care and Clinical Research?
Medicine is plagued by a feedback gap, or perhaps more accurately, a feedback paradox. On the one hand, clinicians are bombarded by feedback. Every day, there are a slew of process and billing metrics to review, providing an accounting of the volume of patients seen, and the intensity of each visit. How thorough was the exam? What procedures may have... Read More
30
Jul
2020
Jill Hagenkord’s Rags To Riches Story Reminds Us Why We Still Admire Entrepreneurs
Entrepreneurial stories, often told through the narrative framework of the hero’s journey, are by now well past the point of cliché. Yet, it’s important, perhaps even instructive, to remind ourselves every now and again about the exceptional, transformative power of entrepreneurship, the can-do thinking it motivates, and the remarkable progress it can propel. This potential emerged as a central theme... Read More
30
Jul
2020
Race and Life Sciences: Where is the Healing?
When I started to go to the J.P. Morgan Healthcare Conference, it was still known as H&Q after boutique bank Hambrecht & Quist that had originated it. This means that, as a journalist, I have been able to watch biopharma grow up over the last 20 years. Those first few events I attended had so little diversity that the upstairs... Read More
23
Jul
2020
Pfizer Secures $2B for COVID-19 Vaccine, BioNTech Raises $500M, & Our Test
When Donald Trump first considered a run for president in 2000, he never rose above 1 percent in the polls. America changed in the early years of the 21st century. Trump was always good at harnessing tabloid media weaknesses to his advantage. When our information commons shifted to a 24/7 advertising-based attention-grab economy on the Internet and TV, he was... Read More
23
Jul
2020
When Raising Drug Prices Helps Patients
Sometimes there are good, patient-friendly reasons to raise drug prices. Proposed legislation that aims to eliminate price hikes on prescription drugs will have unintended consequences. San Francisco-based Jaguar Health, for two years in a row, lost more than $30 million a year. Revenue from its only product, a diarrhea treatment for HIV patients, was only $5.8 million in 2019. The... Read More
22
Jul
2020
Adaptive Trials: Pioneered in the US, Implemented in the UK for COVID-19
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jul
2020
Seer Raises $55 Million; Describes Novel Proteomic Technology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.